WO2022118862A1 - 生体分子構造検出用プローブ、生体分子構造検出用キット、及び生体分子構造の検出方法 - Google Patents
生体分子構造検出用プローブ、生体分子構造検出用キット、及び生体分子構造の検出方法 Download PDFInfo
- Publication number
- WO2022118862A1 WO2022118862A1 PCT/JP2021/043986 JP2021043986W WO2022118862A1 WO 2022118862 A1 WO2022118862 A1 WO 2022118862A1 JP 2021043986 W JP2021043986 W JP 2021043986W WO 2022118862 A1 WO2022118862 A1 WO 2022118862A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biomolecular structure
- detecting
- probe
- specific binding
- biomolecular
- Prior art date
Links
- 239000000523 sample Substances 0.000 title claims abstract description 262
- 238000001514 detection method Methods 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 73
- 239000000126 substance Substances 0.000 claims abstract description 253
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 25
- 230000009870 specific binding Effects 0.000 claims description 143
- 238000002372 labelling Methods 0.000 claims description 129
- 239000007850 fluorescent dye Substances 0.000 claims description 16
- 238000010504 bond cleavage reaction Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 abstract 3
- 125000005647 linker group Chemical group 0.000 description 73
- 210000004027 cell Anatomy 0.000 description 54
- 238000012744 immunostaining Methods 0.000 description 30
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 238000009739 binding Methods 0.000 description 20
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 19
- 125000001931 aliphatic group Chemical group 0.000 description 19
- 230000027455 binding Effects 0.000 description 19
- 108090001008 Avidin Proteins 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 14
- 241000283707 Capra Species 0.000 description 13
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000011616 biotin Substances 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 230000005284 excitation Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 108010026552 Proteome Proteins 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000002981 blocking agent Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 102100034535 Histone H3.1 Human genes 0.000 description 4
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- -1 antibody mimetics Proteins 0.000 description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000002583 anti-histone Effects 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100023919 Histone H2A.Z Human genes 0.000 description 2
- 238000010867 Hoechst staining Methods 0.000 description 2
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical group C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Nonanedioid acid Natural products OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000001822 immobilized cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000008863 intramolecular interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 108091008104 nucleic acid aptamers Proteins 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical group C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 108091008108 affimer Proteins 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N carbodiimide group Chemical group N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical compound NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- IBKZNJXGCYVTBZ-IDBHZBAZSA-M sodium;1-[3-[2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethyldisulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCSSCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 IBKZNJXGCYVTBZ-IDBHZBAZSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FQIYBGJSPWHUQN-UHFFFAOYSA-N sulfanyloxymethane Chemical compound COS FQIYBGJSPWHUQN-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical group ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Definitions
- the present invention relates to a probe for detecting a biomolecular structure, a kit for detecting a biomolecular structure, and a method for detecting a biomolecular structure.
- Fluorescent immunostaining is a method for detecting the expression status of antigens in tissue samples.
- a plurality of types of antigens in the same sample a plurality of types of fluorescent labels having different maximum fluorescence wavelengths have been used.
- the types of fluorescent labels that can be used are limited. Even when fluorescent labels having different maximum fluorescence wavelengths are used, the leakage of fluorescence that is not the detection target into the wavelength range of the fluorescence to be detected hinders the analysis of the accurate expression status of the antigen to be detected. There is.
- Patent Document 1 reports an antibody labeled with a photocleavable label.
- Patent Document 1 describes a method of performing immunostaining with an antibody labeled with a photocleavable label, detecting the photocleavable label, and then irradiating with ultraviolet rays to cut off the label.
- Patent Document 1 a photocleavable label is used, and the label is separated by irradiation with ultraviolet rays.
- the photocleavable label is applied to fluorescent multiplex staining, there is a risk that the photocleavable portion is cleaved by the excitation light for detecting the fluorescent label, and the fluorescent label is unintentionally separated.
- the present invention provides a probe for detecting a biomolecular structure, a kit for detecting a biomolecular structure, and a method for detecting a biomolecular structure, which can repeatedly use the same labeling substance without using a photocleavable label.
- the purpose is to do.
- the present invention includes the following aspects.
- a probe for detecting a biomolecular structure wherein a specific binding substance having a specific binding property to a biomolecular structure and a labeling substance are linked via a linker containing a disulfide bond.
- a biomolecular structure detection kit comprising the biomolecular structure detection probe according to any one of [1] to [3] and a disulfide bond cleavage reagent.
- a kit for detecting a biomolecular structure which comprises a labeling substance and a reagent for cleaving a disulfide bond.
- the labeling substance is a fluorescent dye.
- the step (A) of detecting the first biomolecular structure in the sample containing cells and the disulfide bond in the first biomolecular structure detection probe are cleaved to obtain the above.
- a method for detecting a biomolecular structure which comprises a step (B) of releasing a first labeling substance.
- the specific binding substance having specific binding property to the second biomolecular structure and the second labeling substance are linked via a linker containing a disulfide bond.
- Any of [8] to [10], wherein the first biomolecular structure is a biomolecular structure contained in a first primary probe that specifically binds to a third biomolecular structure contained in the cell.
- the first biomolecular structure is a biomolecular structure contained in a first primary probe that specifically binds to a third biomolecular structure contained in the cell
- the second biomolecular structure is: The method for detecting a biomolecular structure according to [9] or [10], which is a biomolecular structure contained in a second primary probe that specifically binds to the fourth biomolecular structure contained in the cell.
- a probe for detecting a biomolecular structure a probe for detecting a biomolecular structure
- a kit for detecting a biomolecular structure a method for detecting a biomolecular structure, which can repeatedly use the same labeling substance without using a photocleavable label. Will be done.
- Example 1 It is a figure which shows typically the biomolecular structure detection method of one Embodiment. It is a figure which shows typically the biomolecular structure detection method of one Embodiment.
- the outline of the immunostaining method of Example 1 is schematically shown.
- 6 is a fluorescent image showing the result of immunostaining of Example 1.
- 6 is a fluorescent image showing the result of immunostaining of Example 2.
- the outline of the immunostaining method of Example 3 and Comparative Example 1 is schematically shown.
- 3 is a fluorescent image showing the result of immunostaining of Example 3.
- 6 is a fluorescent image showing the result of immunostaining of Comparative Example 1.
- 6 is a fluorescent image showing the result of immunostaining of Reference Example 1.
- 6 is a fluorescent image showing the result of continuous immunostaining of Example 4.
- the data of FIG. 11 is dimensionally compressed (UMAP) to show the results of classifying the cells into five groups.
- UMAP dimensionally compressed
- the figure which showed the position of the cell existing in the fluorescent image of continuous immunostaining as a point it is the figure which showed the position of a cell by the point of the color corresponding to each group.
- the result of superimposing the quantitative value of the expression of a specific protein on the cell position information obtained in FIG. 13 is shown.
- the term “comprise” means that components other than the target component may be included.
- the term “consist of” means that it does not include any component other than the target component.
- the term “consentually of” does not include components other than the target component in a mode in which a component other than the target component exerts a special function (such as a mode in which the effect of the invention is completely lost). means.
- the term “comprise” includes a "consist of" mode and a “consentially of” mode.
- Proteins, peptides, nucleic acids, cells, etc. can be isolated. "Isolated” means the native state or the state separated from other components. What is “isolated” can be substantially free of other components. “Substantially free of other components” means that the content of other components contained in the isolated component is negligible. The content of other components contained in the isolated component is, for example, 10% by mass or less, 5% by mass or less, 4% by mass or less, 3% by mass or less, 2% by mass or less, 1% by mass or less, 0. It can be 5% by mass or less, or 0.1% by mass or less.
- the proteins, peptides, nucleic acids, and cells described herein can be isolated proteins, isolated peptides, isolated nucleic acids, and isolated cells.
- the first aspect of the present invention is for detecting a biomolecular structure in which a specific binding substance having a specific binding property to a biomolecular structure and a labeling substance are linked via a linker containing a disulfide bond. It is a probe.
- Probe means a molecule or molecular complex used to detect a specific biomolecular structure.
- a specific binding substance having a specific binding property to the biomolecular structure to be detected and a labeling substance are linked via a linker containing a disulfide bond. It has a structure.
- Biomolecule means an organic compound contained in a living body.
- the biomolecule may be a molecule that functions in a biological phenomenon.
- the biomolecule may be a molecule artificially synthesized by imitating a natural biomolecule. Examples of biomolecules include peptides, proteins, nucleic acids, lipids, sugars, glycolipids, vitamins, hormones, amino acids, nucleotides and the like.
- Biomolecular structure means a structure contained in a biomolecule.
- the biomolecular structure may be a partial structure of a biomolecule, a partial structure of a primary structure, a partial structure of a secondary structure, or a partial structure of a tertiary structure.
- the biomolecular structure may be a partial structure of a three-dimensional structure composed of a plurality of biomolecules.
- the biomolecule is a peptide or protein
- the biomolecular structure may be, for example, a partial region containing a partial amino acid sequence of the protein, or may be a partial structure of the three-dimensional structure of the protein.
- the structure of the modified amino acid residues may be used.
- the biomolecule is a nucleic acid
- the biomolecular structure may be, for example, a partial nucleotide sequence of the nucleic acid.
- Specific binding substance means a substance having specific binding property to a specific biomolecular structure. "Having specific binding” means having a high binding affinity for a particular biomolecular structure, but very low binding affinity for other biomolecular structures. .. The specific binding substance preferably has high binding property to a specific biomolecular structure, but has little binding property to other biomolecular structures.
- the combination of the biomolecular structure and the specific binding substance is, for example, a combination of a partial structure of a peptide or protein and an antibody, an antibody fragment or an antibody mimic; a partial sequence region of nucleic acid and complementary to the partial sequence.
- the antibody may be in any class or subclass of immunoglobulin.
- the species from which the antibody is derived is not particularly limited, and the antibody may be derived from any organism.
- the antibody is preferably a monoclonal antibody.
- the antibody may be a modified antibody such as a chimeric antibody.
- the antibody fragment means a fragment of an antibody that retains antigen-binding property.
- Examples of the antibody fragment include, but are not limited to, scFv, Fab, F (ab') 2, Fv and the like.
- An antibody mimetic means a non-immunoglobulin molecule having specific binding property to an antigen, similar to an antibody.
- antibody mimetics include, for example, an affibody molecule, affiliin, affimer, affitin, alphabody, antibody, avimer, DARPin. , Finomer, Kunitz domain peptide, monobody, and the like, but are not limited thereto.
- Aptamers are substances that have specific binding properties to target substances.
- the aptamer include nucleic acid aptamers, peptide aptamers and the like.
- Nucleic acid aptamers can be selected, for example, by the systematic evolution of ligand by exponential conduction (SELEX) method or the like.
- Peptide aptamers can be selected by, for example, the Two-hybrid method using yeast.
- the specific binding substance a substance having specific binding property to any biomolecular structure in the cell can be used.
- the specific binding substance has specific binding property to them.
- Antibodies, antibody fragments, antibody mimetics, aptamers and the like can be used.
- a nucleic acid containing a nucleotide sequence complementary to the partial nucleotide sequence, an aptamer, or the like can be used as a specific binding substance.
- the specific binding substance may have specific binding property to the primary probe.
- a "primary probe” is a probe that first binds to the biomolecular structure to be detected.
- the primary probe for example, a biopolymer such as an antibody, an antibody fragment, or a nucleic acid can be used.
- the primary probe is an antibody (primary antibody)
- the specific binding substance may be, for example, an antibody having specific binding property to the constant region of the primary antibody (antibody, antibody fragment, antibody mimetic, aptamer, etc.). ) Can be used.
- labeling substance means a substance that directly or indirectly produces a signal that can be detected by chemical means or physical means.
- Labeling substances include, for example, enzyme labeling such as peroxidase (eg, western wasabi peroxidase), alkaline fluorescein; carboxyfluorescein (FAM), 6-carboxy-4', 5'-dichloro2', 7'-dimethoxyfluorescein (JOE).
- Fluorescein isothiocyanate FITC
- TET tetrachlorofluorescein
- HEX 5'-hexachloro-fluorescein-CE phosphoroamidite
- Cy3, Cy5, Alexa488, Alexa555, Alexa568, Alexa647 and other fluorescent labels FITC
- FITC Fluorescein isothiocyanate
- TET tetrachlorofluorescein
- HEX 5'-hexachloro-fluorescein-CE phosphoroamidite
- Cy3, Cy5, Alexa488, Alexa555, Alexa568, Alexa647 and other fluorescent labels cycl3, Cy5, Alexa488, Alexa555, Alexa568, Alexa647 and other fluorescent labels
- Radioisotope labels electrochemically luminescent labels such as fluorescein complexes; metal nanoparticles and the like, but are not limited thereto.
- Preferred labeling substances include fluorescent labels (fluorescent dyes).
- Linker means a linking portion that connects two substances or a molecule that is used to connect two substances.
- the specific binding substance and the labeling substance are linked via a linker containing a disulfide bond.
- the probe for detecting the biomolecular structure of the present embodiment can be represented by, for example, the following formula (P1).
- Y 1 and Y 2 each independently represent a divalent linking group; L represents a labeling substance; A represents a specific binding substance. ]
- Y 1 and Y 2 each independently represent a divalent linking group.
- the divalent linking group preferably contains a bonding structure.
- the bonded structure means a structure formed by bonding two functional groups by a chemical reaction or an intramolecular interaction. Examples of the chemical reaction forming the bond structure include, but are not limited to, a dehydration condensation reaction and an addition cyclization reaction. It is preferable that the bond structure contained in Y 1 and Y 2 does not contain a disulfide bond.
- the bond structure includes, for example, an amide bond (-CO-NH-), an ester bond (-CO-O-), a thioester bond (-CO-S-), and a phosphate ester bond (-PO 2 -O-). , Urethane bond (-NH-CO-O-), bond containing 1,2,3-triazole ring, etc., but is not limited thereto.
- the binding structure may be an intermolecular interaction such as an avidin-biotin bond.
- the probe for detecting the biomolecular structure of the present embodiment may be represented by the following formula (P1-1), for example.
- Y 11 and Y 12 each independently represent a divalent linking group containing a binding structure; R 11 and R 12 each independently represent a divalent linking group; L is a labeling substance. Represents; A represents a specific binding agent.
- Y 11 and Y 12 each independently represent a divalent linking group containing a binding structure.
- Examples of the bonding structure include those similar to those mentioned in Y 1 and Y 2 above.
- R 11 and R 12 each independently represent a divalent linking group.
- the divalent linking group include a hydrocarbon group which may have a substituent.
- the hydrocarbon group may be an aliphatic hydrocarbon group or an aromatic hydrocarbon group.
- the aliphatic hydrocarbon group may be saturated or unsaturated, but is preferably saturated.
- Examples of the aliphatic hydrocarbon group include a linear or branched aliphatic hydrocarbon group and an aliphatic hydrocarbon group having a ring in its structure.
- the linear aliphatic hydrocarbon group preferably has 1 to 15 carbon atoms, more preferably 1 to 10 carbon atoms, further preferably 1 to 6 carbon atoms, and particularly preferably 1 to 3 carbon atoms.
- a linear alkylene group is preferable.
- the branched aliphatic hydrocarbon group preferably has 2 to 15 carbon atoms, more preferably 2 to 10 carbon atoms, and even more preferably 3 to 6 carbon atoms.
- a branched-chain alkylene group is preferable.
- a cyclic aliphatic hydrocarbon group which may contain a substituent containing a hetero atom in the ring structure (a group obtained by removing two hydrogen atoms from the aliphatic hydrocarbon ring).
- the cyclic aliphatic hydrocarbon group preferably has 3 to 20 carbon atoms, and more preferably 3 to 12 carbon atoms.
- the cyclic aliphatic hydrocarbon group may be a polycyclic group or a monocyclic group.
- the cyclic aliphatic hydrocarbon group may be substituted with a substituent containing a hetero atom (oxygen atom, nitrogen atom, sulfur atom, etc.) as a part of the carbon atom constituting the ring structure.
- the divalent linking group in R 11 and R 12 is an aromatic hydrocarbon group
- the number of carbon atoms is more preferably 6 to 15, and the number of carbon atoms is particularly preferably 6 to 12.
- the aromatic hydrocarbon group is a hydrocarbon group containing an aromatic ring. Examples of the aromatic ring include aromatic hydrocarbon rings such as benzene, naphthalene, anthracene and phenanthrene; and aromatic heterocycles such as triazole ring, pyridine ring and thiophene ring.
- the aromatic hydrocarbon group is a group obtained by removing two hydrogen atoms from the aromatic hydrocarbon ring or aromatic heterocycle (arylene group or heteroarylene group); an aromatic compound containing two or more aromatic rings.
- a group from which two hydrogen atoms have been removed from for example, biphenyl, fluorene, etc.
- one of the hydrogen atoms of the group (aryl group or heteroaryl group) from which one hydrogen atom has been removed from the aromatic hydrocarbon ring or aromatic heterocyclic ring examples thereof include a group in which one is substituted with an alkylene group (a group obtained by removing one hydrogen atom from an aryl group or a heteroaryl group) and the like.
- the alkylene group that replaces the hydrogen atom is preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 4 carbon atoms.
- a part of the hydrogen atom of the hydrogen chain may be substituted with a monovalent group, and the methylene group ( -CH2- ) constituting the hydrocarbon chain may be substituted. It may be partially substituted with a divalent group containing a hetero atom.
- the monovalent group for substituting the hydrogen atom include, but are not limited to, an acyl group, an alkoxy group, a hydroxy group, a carboxy group, an amino group, a thiol group and the like.
- probe for detecting the biomolecular structure of the present embodiment include, but are not limited to, those represented by the following (P1-1-1).
- n1 and n2 each independently represent an integer of 1 to 10; Avi represents avidin or a derivative thereof; L represents a labeling substance; A represents a specific binding substance. ]
- Avi represents avidin or a derivative thereof.
- the avidin derivative include streptavidin, neutral avidin and the like.
- Avidin represented by Avi or a derivative thereof is bound to the biotin moiety by an intramolecular interaction.
- n1 and n2 are independently integers of 1 to 10.
- an integer of 1 to 6 is preferable, an integer of 1 to 3 is more preferable, and 2 or 3 is further preferable.
- Avi represents avidin or a derivative thereof; L represents a labeling substance; A represents a specific binding substance.
- the probe for detecting the biomolecular structure of the present embodiment contains a disulfide bond in the linker portion between the specific binding substance and the labeling substance, the labeling substance can be separated at any timing by cleaving the disulfide bond.
- the disulfide bond can be easily cleaved with a reducing agent such as tris (2-carboxyethyl) phosphine (TCEP), 2-mercaptoethanol, dithiothreitol (DTT). Since the disulfide bond is not cleaved by light, it does not cleave when irradiated with the excitation light required for fluorescence observation.
- a second aspect of the present invention is a kit for detecting a biomolecular structure, which comprises the probe for detecting a biomolecule according to the above-mentioned aspect and a reagent for cleaving a disulfide bond.
- the biomolecule detection probe is the same as the biomolecule detection probe of the above-described embodiment.
- the specific binding substance is, for example, a specific binding substance (antibody, antibody fragment, antibody) having specific binding property to a primary probe (for example, a primary antibody). It may be a mimic, an aptamer, etc.).
- the primary probe is an antibody derived from a specific species of animal (for example, a mouse antibody)
- the specific binding substance of the probe for detecting a biological molecule may have specific binding property to a constant region of the antibody.
- An antibody derived from a species of animal for example, a goat anti-mouse antibody
- an antibody fragment thereof can be used.
- the biomolecular structure detection kit of the present embodiment contains a reagent for cleaving a disulfide bond in addition to the above-mentioned biomolecule detection probe.
- the reagent for cleaving the disulfide bond is not particularly limited as long as it can cleave the disulfide bond.
- Examples of the cleaving reagent include reducing agents such as TCEP, 2-mercaptoethanol, and DTT. TCEP is preferred as the cleavage reagent because of its high stability and selectivity.
- a third aspect of the present invention is a linker for linking a specific binding substance having specific binding property to a biomolecular structure and a labeling substance, and the linker containing a disulfide bond and the linker are bound to the linker.
- a kit for detecting a biomolecular structure which comprises a labeling substance that can be bonded or bonded and a reagent for cleaving the disulfide bond.
- the kit of this embodiment contains a linker for linking a specific binding substance having specific binding property to a biomolecular structure and a labeling substance.
- the linker may have, for example, a functional group that reacts with a functional group contained in a specific binding substance or a labeling substance.
- the linker may have an amine-reactive group.
- An amine-reactive group is a functional group that reacts with an amine.
- the amine-reactive group is not particularly limited, and known ones can be used.
- amine-reactive group examples include an N-hydroxy ester (NHS-ester) group, a carboxy group, an isocyanate group, an isothiocyanate group, a sulfonyl chloride group, an aldehyde group, a carbodiimide group, an acylazide group, an epoxy group and an imide ester group.
- NHS-ester N-hydroxy ester
- linkage between the linker and the specific binding substance or labeling substance may be carried out by an avidin-biotin bond.
- the linker may contain a group derived from biotin.
- linker examples include those represented by the following formula (L1).
- V 1 and V 2 each independently represent a functional group or a group derived from biotin; R 11 and R 12 each independently represent a divalent linking group. ]
- V 1 and V 2 each independently represent a functional group or a group derived from biotin.
- the functional groups in V 1 and V 2 are functional groups capable of reacting with the functional groups of the specific binding substance or the labeling substance to form a bonded structure.
- the functional group in V 1 and V 2 includes an amine-reactive group as described above.
- R 11 and R 12 each independently represent a divalent linking group.
- R 11 and R 12 are the same as R 11 and R 12 in the above formula (P1-1).
- the labeling substance may be bound to the linker.
- the labeling substance may be provided in a state where it is not bound to the linker.
- the labeling substance has a structure capable of binding to the linker.
- the labeling substance may have a functional group capable of reacting with the functional group of the linker to form a bonded structure.
- the linker contains a group derived from biotin, avidin or an avidin derivative may be added. Examples of the avidin derivative include the same as above. If the labeling substance is provided unbound to the linker, the user may perform a ligation reaction between the linker and the labeling substance before use.
- Cutting reagent As the cutting reagent, the same ones as those mentioned in the kit of the first embodiment can be used.
- the kit of this embodiment does not contain a specific binding substance, and the user can select any specific substance.
- the user can prepare a probe for detecting a biomolecule by carrying out a binding reaction between an arbitrary specific binding substance and a linker before use.
- the kit according to the second aspect or the third aspect may include other elements in addition to the above elements.
- Other elements include, for example, labeling reagent detection reagents, sample preparation reagents, diluents, buffers (blocking buffer, washing buffer, etc.), instruction manuals, and the like.
- the kit of this embodiment can be used for the biomolecular structure detection method described later.
- the specific binding substance having specific binding property to the first biomolecular structure and the first labeling substance are linked via a linker containing a disulfide bond.
- This is a method for detecting a biomolecular structure which comprises a step (B) of cleaving the above-mentioned first labeling substance to release the labeling substance.
- the method of this embodiment is a method of detecting a target biomolecular structure in a sample containing cells.
- the "sample containing cells” is not particularly limited as long as it is a sample containing cells.
- the sample containing cells may be a tissue section, a cell suspension, a body fluid sample containing cells, or the like.
- the cell may be a cell of any organism.
- FIG. 1 is a diagram schematically showing an example of the method of the present embodiment. The method of this embodiment can be carried out using the probe for detecting the biomolecular structure of the first aspect.
- 1 is a sample containing cells.
- Sample 1 contains biomolecules 10a and 10b. Each of the biomolecule 10a and the biomolecule 10b is a biomolecule containing a biomolecular structure to be detected.
- Reference numeral 20a is a specific binding substance that specifically binds to the biomolecular structure contained in the biomolecule 10a.
- 30a is a labeling substance.
- the specific binding substance 20a and the labeling substance 30a are linked via a linker 40a containing a disulfide bond, and form a probe P1 for detecting a biomolecular structure.
- Reference numeral 20b is a specific binding substance that specifically binds to the biomolecular structure contained in the biomolecule 10b.
- 30b is a labeling substance.
- the specific binding substance 20b and the labeling substance 30b are linked via a linker 40b containing a disulfide bond, and form a probe P2 for detecting a biomolecular structure.
- biomolecules 10a and 10b are the same as those exemplified in the above [Probe for detecting biomolecular structure].
- the biomolecules 10a and 10b are, for example, peptides or proteins.
- Examples of the specific binding substances 20a and 20b include the same as those exemplified in the above [Probe for detecting biomolecular structure].
- the specific binding substances 20a and 20b are, for example, an antibody or an antibody fragment.
- labeling substances 30a and 30b include those similar to those exemplified in the above [Probe for detecting biomolecular structure].
- the labeling substances 30a and 30b are, for example, fluorescent dyes.
- Examples of the linkers 40a and 40b are the same as those exemplified in the above [Probe for detecting biomolecular structure].
- the labeling substances 30a and 30b may be the same or different.
- the labeling substance 30a is a fluorescent dye
- the labeling substance 30b is also a fluorescent dye.
- the fluorescent dyes of the labeling substances 30a and 30b may be the same or different.
- the specific binding substance (specific binding substance 20a) having specific binding property to the first biomolecular structure and the first labeling substance (labeling substance 30a) form a disulfide bond.
- the first biomolecular structure detection probe (biomolecular structure detection probe P1) linked via the inclusion linker (linker 40a) the first biomolecule in the sample (sample 1) containing cells is used.
- the molecular structure (biomolecular structure contained in the biomolecule 10a) is detected (see FIG. 1 (A)).
- the biomolecular structure detection probe P1 is the first biomolecular structure detection probe.
- the sample 1 is treated with the biomolecular structure detection probe P1.
- the probe P1 for detecting the biomolecular structure binds to the biomolecule 10a via the specific binding substance 20a.
- the method for treating the sample 1 with the biomolecular structure detection probe P1 can be appropriately selected according to the type of the specific binding substance 20a.
- a solution of the biomolecular structure detection probe P1 in which the biomolecular structure detection probe P1 is dissolved in an appropriate buffer for example, phosphate buffer, Tris hydrochloride buffer, PBS, etc.
- an appropriate buffer for example, phosphate buffer, Tris hydrochloride buffer, PBS, etc.
- the probe P1 for detecting the biomolecular structure can be bound to the biomolecule 10a.
- the incubation temperature and the incubation time can be appropriately selected depending on the type of the specific binding substance 20a.
- the specific binding substance 20a is an antibody or an antibody fragment
- the incubation temperature may be 20 to 40 ° C (preferably 30 to 40 ° C).
- the incubation time may be about 30 to 120 minutes.
- the sample 1 may be washed with a washing buffer or the like. As a result, the unbound biomolecular structure detection probe P1 can be removed.
- the sample 1 may be blocked with a blocking agent before the treatment with the biomolecular structure detection probe P1.
- a blocking agent include, but are not limited to, bovine serum albumin, skim milk, casein, gelatin and the like.
- the signal of the labeling substance 30a of the biomolecular structure detection probe P1 is detected.
- the biomolecular structure to which the specific binding substance 20a is bound can be indirectly detected.
- the method for detecting the signal of the labeling substance 30a can be appropriately selected depending on the type of the labeling substance 30a.
- the labeling substance 30a is a fluorescent dye
- the signal of the labeling substance 30a can be detected by irradiating light with the excitation wavelength of the fluorescent dye and detecting the fluorescence using a fluorescence microscope.
- the disulfide bond in the biomolecular structure detection probe P1 can be cleaved by using a disulfide bond cleavage reagent.
- the cleavage reagent include the same as those mentioned in the above [Biomolecular structure detection kit].
- the concentration of the cleaving reagent is not particularly limited, and can be appropriately selected depending on the type of the cleaving reagent.
- the concentration of the cleavage reagent may be an amount sufficient for cleavage of the disulfide bond in the probe P1 for detecting the biomolecular structure.
- the concentration of the reducing agent can be, for example, 5 mM or more, 10 mM or more, 20 mM or more, or 30 mM or more.
- the upper limit of the concentration of the reducing agent is not particularly limited, but may be, for example, 100 mM or less, 80 mM or less, 70 mM or less, 60 mM or less, or 50 mM or less.
- the treatment time with the reducing agent can be, for example, 10 minutes or more, 15 minutes or more, 20 minutes or more, 25 minutes or more, or 30 minutes or more.
- the upper limit of the treatment time with the reducing agent is not particularly limited, but may be, for example, 200 minutes or less, 150 minutes or less, or 120 minutes or less from the viewpoint of not denaturing the biomolecule.
- the concentration can be 5 to 50 mM and the treatment time can be about 20 to 40 minutes.
- the processing temperature may be 20 to 40 ° C.
- the labeling substance 30a is separated from the biomolecular structure detection probe P1 and released. Therefore, the signal of the labeling substance 30a in the sample 1 disappears.
- the sample After the treatment with the cutting reagent, the sample may be washed with a washing buffer or the like. Thereby, the liberated labeling substance 30a can be removed.
- the method of the present embodiment may include other steps in addition to the above steps (A) and (B).
- a specific binding substance having specific binding property to the second biomolecular structure and the second labeling substance are linked via a linker containing a disulfide bond.
- Steps of detecting the second biomolecular structure in the sample using the second biomolecular structure detection probe (C) (see FIG. 1 (C)); and in the biomolecular structure detection probe P2. Examples thereof include a step (D) (see FIG. 1 (D)) of cleaving the disulfide bond to release the second labeling substance.
- the method of the present embodiment can further include the step (C) after the step (B).
- the biomolecular structure detection probe P2 is the second biomolecular structure detection probe.
- the sample 1 after the step (B) is treated with the biomolecular structure detection probe P2.
- the probe P2 for detecting the biomolecular structure binds to the biomolecule 10b via the specific binding substance 20b.
- the step (C) can be performed in the same manner as the above step (A) except that the biomolecular structure detection probe P2 is used instead of the biomolecular structure detection probe P1.
- the signal of the labeling substance 30b of the biomolecular structure detection probe P2 is detected.
- the biomolecular structure to which the specific binding substance 20b is bound can be indirectly detected.
- the method for detecting the signal of the labeling substance 30b can be appropriately selected depending on the type of the labeling substance 30b.
- the labeling substance 30b is a fluorescent dye
- the signal of the labeling substance 30b can be detected by irradiating light with the excitation wavelength of the fluorescent dye and detecting the fluorescence using a fluorescence microscope.
- the labeling substance 30b may be the same as or different from the labeling substance 30a.
- the labeling substance 30a disappears in the sample 1 by the step (B). Therefore, even if the labeling substance 30b is the same as the labeling substance 30a, in the step (C), only the labeling substance 30b bound to the biomolecule 10b can be detected.
- Step (D) The method of the present embodiment can further include the step (D) after the step (C). By performing the step (D), the signal of the labeling substance 30b in the sample 1 can be extinguished.
- the step (D) can be performed in the same manner as the above step (B).
- the method of the present embodiment may further include a step (E) in which the step (C) and the step (D) are repeated by changing the type of the specific binding substance in the probe for detecting the biomolecular structure. .. It is preferable to use different specific binding substances for each cycle of step (C) and step (D).
- the labeling substance in the probe for detecting the biomolecular structure may or may not be changed every cycle.
- the number of repetitions of the step (C) and the step (D) is not particularly limited and may be any number.
- the number of repetitions of the step (C) and the step (D) is, for example, 1 time or more, 2 times or more, 3 times or more, 5 times or more, 10 times or more, 20 times or more, 30 times or more, 40 times or more, or 50 times. It may be more than once.
- the upper limit of the number of repetitions of the step (C) and the step (D) is not particularly limited, but may be, for example, 500 times or less, 400 times or less, 300 times or less, 200 times or less, or 100 times or less.
- the number of repetitions of the step (C) and the step (D) is, for example, 1 to 100 times, 1 to 90 times, 1 to 80 times, 1 to 70 times, 1 to 60 times, 1 to 50 times, 1 to 40 times. It can be 1 to 30 times, 1 to 20 times, 1 to 10 times, 1 to 5 times, and the like.
- the disulfide bond in the first biomolecular structure detection probe is cleaved to carry out the labeling substance. Is released. Therefore, when the second biomolecular structure is detected by using the second biomolecular structure detection probe, the labeling substance of the first biomolecular structure detection probe does not interfere with each other. Therefore, the biomolecular structure detection operation can be repeated using the same sample. In the method of the present embodiment, since the same labeling substance can be used repeatedly, the number of repetitions of the detection operation is not limited to the type of labeling substance.
- the labeling substance since a disulfide bond is used for the cleavage structure of the labeling substance, the labeling substance is not separated by the excitation light even when a fluorescent dye is used for the labeling substance.
- the labeling substance can be cleaved under reducing conditions to the extent that the biomolecule is not denatured. Therefore, after identifying a cell having a desired biomolecular structure by the method of the present embodiment, RNA or the like can be extracted from the cell and suitably used for transcriptome analysis or the like.
- the method of this embodiment can also be performed using a primary probe.
- the biomolecular structure to which the biomolecular structure detection probe is bound may be the biomolecular structure included in the primary probe.
- the first biomolecular structure to which the first biomolecular structure detecting probe is bound may be the biomolecular structure contained in the first primary probe.
- the first primary probe may be specifically bound to a third biomolecular structure contained in the cells in the sample.
- the second biomolecular structure to which the second biomolecular structure detecting probe is bound may be the biomolecular structure contained in the second primary probe.
- the second primary probe may be specifically bound to the fourth biomolecular structure contained in the cells in the sample.
- FIG. 2 is a diagram schematically showing an example of a method using a primary probe.
- the specific binding substance 20a is used as a first primary probe for binding to the biomolecular structure contained in the biomolecule 10a.
- 21a is a specific binding substance having a specific binding activity on the biomolecular structure of the specific binding substance 20a (first primary probe).
- the specific binding substance 21a and the labeling substance 30a are linked via a linker 40a containing a disulfide bond, and form a probe P3 for detecting a biomolecular structure.
- the biomolecular structure detection probe P3 is used as the first biomolecular structure detection probe.
- the specific binding substances 20a and 21a are, for example, an antibody or an antibody fragment.
- the specific binding substance 20b is used as a second primary probe for binding to the biomolecular structure contained in the biomolecule 10b.
- 21b is a specific binding substance having a specific binding activity on the biomolecular structure of the specific binding substance 20b (second primary probe).
- the specific binding substance 21b and the labeling substance 30b are linked via a linker 40b containing a disulfide bond, and form a probe P4 for detecting a biomolecular structure.
- the biomolecular structure detection probe P4 is used as a second biomolecular structure detection probe.
- Specific binding substances 20b, 21b are, for example, antibodies or antibody fragments.
- the method of this modification includes step (A').
- a cell is subjected to a first primary probe (specific binding substance 20a) having specific binding property to a third biomolecular structure (biomolecular structure contained in the biomolecule 10a).
- a first biomolecule in which a specific binding substance having a property (specific binding substance 21a) and a first labeling substance (labeling substance 30a) are linked via a linker (linker 40a) containing a disulfide bond.
- the sample 1 is treated with the specific binding substance 20a as the first primary probe.
- the specific binding substance 20a binds to the biomolecule 10a in the sample 1.
- the sample 1 is treated with the biomolecular structure detection probe P3.
- the probe P3 for detecting the biomolecular structure binds to the specific binding substance 20a via the specific binding substance 21a.
- a complex of the biomolecule 10a, the first primary probe (specific binding substance 20a), and the probe P3 for detecting the biomolecular structure is formed.
- the method for treating the sample 1 with the specific binding substance 20a and the biomolecular structure detection probe P3 can be carried out in the same manner as the treatment of the sample 1 with the biomolecular structure detection probe P1 in the above step (A).
- the sample 1 After the treatment with the first primary probe (specific binding substance 20a), the sample 1 may be washed with a washing buffer or the like. Thereby, the unbound specific binding substance 20a can be removed. Further, after the treatment with the biomolecular structure detection probe P3, the sample 1 may be washed with a washing buffer or the like. As a result, the unbound biomolecular structure detection probe P3 can be removed.
- the sample 1 may be blocked with a blocking agent before the treatment with the first primary probe (specific binding substance 20a). By performing blocking, the non-specific binding of the specific binding substance 20a can be reduced.
- the sample 1 may be blocked with a blocking agent before the treatment with the biomolecular structure detection probe P3. By blocking, the non-specific binding of the biomolecular structure detection probe P3 can be reduced. Examples of the blocking agent include the same as above.
- the signal of the labeling substance 30a of the biomolecular structure detection probe P3 is detected.
- the biomolecular structure of the biomolecule 10a bound via the specific binding substance 20a and the specific binding substance 21a can be indirectly detected.
- the method for detecting the signal of the labeling substance 30a can be carried out in the same manner as in the above step (A).
- Step (B') See FIG. 2 (B')
- the disulfide bond in the first biomolecular structure detection probe biomolecular structure detection probe P3
- the first labeling substance labeling substance 30a.
- the step (B') can be performed in the same manner as the above step (B).
- the method of this modification may include a step (C') in addition to the above steps (A') and (B').
- the step (C') uses a second primary probe (specific binding substance 20b) having specific binding property to the fourth biomolecular structure (biomolecular structure contained in the biomolecule 10b) to generate cells. Processing the containing sample (Sample 1) and binding the second primary probe to the second biomolecular structure in the sample; and specific to the second biomolecular structure contained in the second primary probe.
- a second labeling substance (specific binding substance 21b) having a binding property and a second labeling substance (labeling substance 30b) are linked via a linker (linker 40b) containing a disulfide bond.
- the sample 1 after the step (B') is treated with the specific binding substance 20b as the second primary probe.
- the specific binding substance 20b binds to the biomolecule 10b in the sample 1.
- the sample 1 is treated with the biomolecular structure detection probe P4.
- the probe P4 for detecting the biomolecular structure binds to the specific binding substance 20b via the specific binding substance 21b.
- a complex of the biomolecule 10b, the second primary probe (specific binding substance 20b), and the biomolecular structure detection probe P4 is formed.
- the method for treating the sample 1 with the specific binding substance 20b can be carried out in the same manner as in the above step (A') except that the specific binding substance 20b is used instead of the specific binding substance 20a.
- the method for processing the sample 1 by the biomolecular structure detection probe P4 may be the same as the above step (A') except that the biomolecular structure detection probe P4 is used instead of the biomolecular structure detection probe P3. can.
- the signal of the labeling substance 30b of the biomolecular structure detection probe P4 is detected.
- the biomolecular structure of the biomolecule 10b bound via the specific binding substance 20b and the specific binding substance 21b can be indirectly detected.
- the method for detecting the signal of the labeling substance 30b can be carried out in the same manner as in the above step (A).
- the method of this modification may include a step (D') after the above step (C').
- the disulfide bond in the second biomolecular structure detection probe biomolecular structure detection probe P4
- the step (D') can be performed in the same manner as the above step (D).
- the method of the present embodiment further changes the type of the primary probe and the type of the specific binding substance in the probe for detecting the biomolecular structure, and repeats the step (C') and the step (D') (E). ') May be included. It is preferable to use different specific binding substances in the primary probe and the probe for detecting the biomolecular structure for each step (C') and step (D') cycle.
- the labeling substance in the probe for detecting the biomolecular structure may or may not be changed every cycle.
- the number of repetitions of the step (C') and the step (D') is not particularly limited and may be any number.
- the number of repetitions of the step (C') and the step (D') is, for example, 1 time or more, 2 times or more, 3 times or more, 5 times or more, 10 times or more, 20 times or more, 30 times or more, 40 times or more, Alternatively, it may be 50 times or more.
- the upper limit of the number of repetitions of the step (C') and the step (D') is not particularly limited, but may be, for example, 500 times or less, 400 times or less, 300 times or less, 200 times or less, or 100 times or less. ..
- the number of repetitions of the step (C') and the step (D') is, for example, 1 to 100 times, 1 to 90 times, 1 to 80 times, 1 to 70 times, 1 to 60 times, 1 to 50 times, 1 to 1 to It can be 40 times, 1 to 30 times, 1 to 20 times, 1 to 10 times, 1 to 5 times, and the like.
- the biomolecular structure detection probe is bound to the biomolecular structure in the sample to be detected via the primary probe. Therefore, any biomolecular structure can be detected by using a primary probe having specific binding property to any biomolecular structure.
- a probe containing a specific binding substance for the specific biomolecular structure may be used as the probe for detecting the biomolecular structure. ..
- a probe prepared in advance according to the type of the primary probe can be used as the probe for detecting the biomolecular structure.
- linker a commercially available EZ-link Sulfo-NHS-SS-Biotin (Thermo Fisher) was used.
- Binding of linker and specific binding substance As the first specific binding substance, a rat anti-mouse IgG antibody (Rat anti-mouse IgG, Jackson Immuno Research) was used. Binding of the linker to the first specific binding agent was performed according to the instructions attached to the linker.
- FITC-labeled avidin As the labeling substance, FITC-labeled avidin (Avidin-FITC, Funakoshi) or Alexa 555-labeled avidin (Streptavidin, Alexa Fluor 555 conjugate, Thermo Fisher) was used.
- the linker and the labeling substance were combined by reacting in 0.1 M aqueous sodium hydrogen carbonate solution (pH 8.3) at room temperature for 30 minutes.
- the second method is the same as the method for producing the first biomolecular structure detection probe, except that a goat anti-rabbit IgG antibody (Goat anti-rabbit IgG, Jackson Immuno Research) was used as the specific binding substance.
- a probe for detecting the biomolecular structure was prepared.
- Example 1 The outline of the immunostaining method of Example 1 is schematically shown in FIG.
- a mouse anti- ⁇ -actin antibody (Anti- ⁇ Actin, Abcam) was reacted with the sample as the primary antibody (first primary probe), and then the first biomolecular structure detection probe was reacted as the secondary antibody. Then, it was treated with 50 mM TCEP-HCl for 30 minutes. Then, a rabbit anti-H2AZ antibody (Anti-H2AZ, Abcam) was reacted with the sample as a primary antibody (second primary probe), and then the second biomolecular structure detection probe was reacted as a secondary antibody. Specifically, the procedure was as follows.
- the cells were fixed by adding 4% paraformaldehyde (paraformaldehyde, Nacalai Tesque) to the cells cultured in the cell culture dish and reacting for 15 minutes. 0.5% Triton X-100 was added to the immobilized cells and allowed to react for 5 minutes for permeation treatment. Then, a blocking solution (Blocking One-P, Nacalai Tesque) was added and reacted for 10 minutes to perform blocking. The primary antibody (Anti- ⁇ Actin, Anti-H2AZ, etc.) was then diluted with a 10% blocking solution to the appropriate concentration and reacted with the cells at room temperature for 45 minutes.
- paraformaldehyde paraformaldehyde, Nacalai Tesque
- the cells were then washed with PBS for 5 minutes x 3 times and reacted with linker-labeled rat anti-mouse IgG antibody or goat anti-rabbit IgG antibody (diluted 500-fold with 10% blocking solution) at room temperature for 45 minutes. .. After the reaction, the cells were washed with PBS for 5 minutes x 3 times, and fluorescently labeled avidin diluted 1000-fold with a 10% blocking solution was reacted at room temperature for 45 minutes. After the reaction, the cells were washed with PBS for 5 minutes x 3 times, and fluorescence observation was performed. After fluorescence observation, 50 mM TCEP was added to the cells and treated at room temperature for 30 minutes. After the reaction, the cells were washed with PBS for 5 minutes x 3 times, and fluorescence observation was performed again.
- ⁇ -actin can be detected based on the fluorescence of FITC by reacting the mouse anti- ⁇ -actin antibody as a primary antibody and then reacting with the first biomolecular structure detection probe. (1st stage image). Then, by treating with 50 mM TCEP for 30 minutes, FITC was liberated and the fluorescence of FITC disappeared (second stage, rightmost image).
- H2AZ could be detected based on the fluorescence of FITC (third stage image). .. Then, by treating with 50 mM TCEP for 30 minutes, FICT was liberated and the fluorescence of FITC disappeared (4th stage, rightmost image).
- the labeled substance can be released at any timing by using a probe for detecting the biomolecular structure in which the specific binding substance and the labeled substance are linked via a linker containing a disulfide bond. It was also confirmed that immunostaining can be repeated.
- Example 2 As the probe for detecting the biomolecular structure, the second probe for detecting the biomolecular structure prepared in Example 1 was used. A rabbit anti-H2AZ antibody was used as the primary antibody, and the sample was reacted in the same manner as described above, and then the probe for detecting the biomolecular structure was reacted as the secondary antibody (Staining). It was then treated with 0 mM, 1 mM, 5 mM, 20 mM, or 50 mM TCEP-HCl (TCEP). In addition, TCEP-treated samples were reacted with Alexa555-labeled goat anti-rabbit antibody (Goat anti-Rabbit IgG, Thermo Fisher) or avidin-labeled FITC (Re-steining).
- Alexa555-labeled goat anti-rabbit antibody Goat anti-Rabbit IgG, Thermo Fisher
- avidin-labeled FITC Re-steining
- H2AZ could be detected based on the fluorescence of FITC by reacting the rabbit anti-H2AZ antibody as a primary antibody and then reacting with the probe for detecting the biomolecular structure (FIG. 5, FIG. 5). 1st stage image). Then, by treating with TCEP of 0 to 50 mM for 30 minutes, FICT was released depending on the concentration of TCEP, and the fluorescence of FITC disappeared (FIG. 5, 2nd stage image). Furthermore, when the biotin-labeled FITC was reacted with the sample after TCEP treatment, almost no fluorescence of FITC could be detected.
- Example 3 Comparative Example 1
- the outline of the immunostaining method of Example 3 and Comparative Example 1 is schematically shown in FIG.
- Alexa555-labeled mouse anti-histone H3.1 antibody was used as the primary antibody
- Al2xa488-labeled goat anti-mouse antibody was used as the secondary antibody.
- the Alexa555-labeled antibody used as the primary antibody contains a disulfide bond or a 2-nitrobenzyl group at the linker site between the antibody and Alexa555.
- Example 3 A mouse anti-histon H3.1 antibody (Anti-H3.1 antibody, prepared by Okawa Laboratory, Institute of Biodefense Medicine, Kyushu University) was used as a specific binding substance, and Avidin-labeled Alexa555 (Streptavidin, Alexa Fluor 555 conjugate) was used as a labeling substance.
- a probe for detecting a biomolecular structure was produced by the same method as that for producing the above-mentioned first probe for detecting a biomolecular structure, except that the Thermo Fisher) was used.
- the probe for detecting the biomolecular structure was used as the primary antibody and the Alexa488-labeled goat anti-mouse antibody (Goat antibody-Mouse IgG Alexa Fluor 488, Thermo Fisher) was used as the secondary antibody. Immunostaining was performed. In addition, Hoechst staining was performed and imaging was performed at a wavelength of 405 nm.
- the photocleaving linker one containing a 2-nitrobenzyl group as a photocleaving group was used (PC-Biotin-PEG4-NHS carbonate, Funakoshi).
- Immunostaining was performed in the same manner as in Example 1 except that the Alexa555-labeled mouse anti-histone H3.1 antibody containing the photocleaving linker was used as the primary antibody. In addition, Hoechst staining was performed and imaging was performed at a wavelength of 405 nm.
- Fig. 8 The results are shown in Fig. 8. As shown in FIG. 8, the fluorescence of Alexa555 faded from the start of irradiation at the excitation wavelength, and it was difficult to detect the fluorescence of Alexa555 30 seconds and 60 seconds later. On the other hand, since the fluorescence of Alexa488 was detected, it was confirmed that the primary antibody remained. Therefore, it was considered that the fading of Alexa555 was due to the cleavage of the photocleaving group by the excitation light irradiation and the release of Alexa555.
- Example 4 ⁇ Preparation of probe for biomolecular structure detection> Each biomolecular structure detection probe was prepared by the same method as in Example 1 except that an antibody specific to each protein shown in FIG. 10 was used as a specific binding substance.
- the sample after TCEP treatment was immunostained in the same manner as above except that a linker-labeled anti-CD68 mouse IgG antibody was used, and fluorescence observation was performed. Then, TCEP treatment was performed in the same manner as above. The same treatment was repeated using a mouse IgG antibody that specifically binds to each protein shown in FIG. 10.
- Example 5 ⁇ Preparation of probe for biomolecular structure detection> Each biomolecular structure detection probe was prepared by the same method as in Example 1 except that an antibody specific to each protein shown in FIG. 11 was used as a specific binding substance.
- Continuous immunostaining was performed in the same manner as in Example 10 except that an antibody specific for each protein shown in FIG. 11 was used.
- FIG. 14 shows the result of superimposing the quantitative value of the expression of a specific protein on the cell position information obtained in FIG. 13. From the results shown in FIG. 14, it was shown that cells with high expression of a specific protein were spatially biased.
- proteome analysis is possible by performing continuous staining using a probe for biomolecular structure detection containing a disulfide bond at the linker site.
- a probe for detecting a biomolecular structure a probe for detecting a biomolecular structure
- a kit for detecting a biomolecular structure a method for detecting a biomolecular structure, which can repeatedly use the same labeling substance without using a photocleavable label. Will be done.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
本願は、2020年12月1日に、日本に出願された特願2020-199800号に基づき優先権を主張し、その内容をここに援用する。
[1]生体分子構造に対して特異的結合性を有する特異的結合物質と、標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、生体分子構造検出用プローブ。
[2]前記特異的結合物質が抗体である、[1]に記載の生体分子構造検出用プローブ。
[3]前記標識物質が蛍光色素である、[1]又は[2]に記載の生体分子構造検出用プローブ。
[4][1]~[3]のいずれか1つに記載の生体分子構造検出用プローブと、ジスルフィド結合の切断試薬と、を含む、生体分子構造検出用キット。
[5]生体分子構造に対して特異的結合性を有する特異的結合物質と標識物質とを連結するためのリンカーであって、ジスルフィド結合を含むリンカーと、前記リンカーに結合している若しくは結合可能な標識物質と、ジスルフィド結合の切断試薬と、を含む、生体分子構造検出用キット。
[6]前記特異的結合物質が抗体である、[5]に記載の生体分子構造検出用キット。
[7]前記標識物質は蛍光色素である、[5]又は[6]に記載の生体分子構造検出用キット。
[8]第1の生体分子構造に対して特異的結合性を有する特異的結合物質と、第1の標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、第1の生体分子構造検出用プローブを用いて、細胞を含む試料中の第1の生体分子構造を検出する工程(A)と、前記第1の生体分子構造検出用プローブ中の前記ジスルフィド結合を切断して、前記第1の標識物質を遊離させる工程(B)と、を含む、生体分子構造の検出方法。
[9]前記工程(B)後、第2の生体分子構造に対して特異的結合性を有する特異的結合物質と、第2の標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、第2の生体分子構造検出用プローブを用いて、前記試料中の前記第2の生体分子構造を検出する工程(C)、をさらに含む、[8]に記載の生体分子構造の検出方法。
[10]前記第1の標識物質と前記第2の標識物質とが、同一の標識物質である、[9]に記載の生体分子構造の検出方法。
[11]前記第1の生体分子構造が、前記細胞が含む第3の生体分子構造に特異的に結合する第1の一次プローブが含む生体分子構造である、[8]~[10]のいずれか1つに記載の生体分子構造の検出方法。
[12]前記第1の生体分子構造が、前記細胞が含む第3の生体分子構造に特異的に結合する第1の一次プローブが含む生体分子構造であり、前記第2の生体分子構造が、前記細胞が含む第4の生体分子構造に特異的に結合する第2の一次プローブが含む生体分子構造である、[9]又は[10]に記載の生体分子構造の検出方法。
本発明の第1の態様は、生体分子構造に対して特異的結合性を有する特異的結合物質と、標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、生体分子構造検出用プローブである。
<第1実施形態>
本発明の第2の態様は、前記態様の生体分子検出用プローブと、ジスルフィド結合の切断試薬と、を含む生体分子構造検出用キットである。
生体分子検出用プローブは、前記態様の生体分子検出用プローブと同じである。本実地形態のキットが含む生体分子検出用プローブにおいて、特異的結合物質は、例えば、一次プローブ(例えば、一次抗体)に対して特異的結合性を有する特異的結合物質(抗体、抗体断片、抗体模倣体、又はアプタマー等)であってもよい。例えば、一次プローブが特定種の動物由来の抗体(例えば、マウス抗体)である場合、生体分子検出用プローブの特異的結合物質としては、前記抗体の定常領域に対して特異的結合性を有する他種の動物由来の抗体(例えば、ヤギ抗マウス抗体)若しくはその抗体断片等を用いることができる。
本実施形態の生体分子構造検出用キットは、上記生体分子検出用プローブに加えて、ジスルフィド結合の切断試薬を含む。ジスルフィド結合の切断試薬は、ジスルフィド結合を切断可能なものであれば、特に限定されない。切断試薬としては、例えば、TCEP、2-メルカプトエタノール、DTT等の還元剤が挙げられる。切断試薬としては、安定性及び選択性が高いことから、TCEPが好ましい。
本発明の第3の態様は、生体分子構造に対して特異的結合性を有する特異的結合物質と標識物質とを連結するためのリンカーであって、ジスルフィド結合を含むリンカーと、前記リンカーに結合している若しくは結合可能な標識物質と、前記ジスルフィド結合の切断試薬と、を含む、生体分子構造検出用キットである。
本実施形態のキットは、生体分子構造に対して特異的結合性を有する特異的結合物質と標識物質とを連結するためのリンカーを含む。前記リンカーは、例えば、特異的結合物質又は標識物質が含む官能基と反応する官能基を有するものであってもよい。例えば、特異的結合物質がアミノ基を有する場合、リンカーは、アミン反応性基を有していてもよい。アミン反応性基とは、アミンと反応する官能基である。アミン反応性基は、特に限定されず、公知のものを用いることができる。アミン反応性基としては、例えば、N-ヒドロキシエステル(NHS-エステル)基、カルボキシ基、イソシアネート基、イソチオシアネート基、スルホニルクロライド基、アルデヒド基、カルボジイミド基、アシルアザイド基、エポキシ基、イミドエステル基等が挙げられるが、これらに限定されない。
標識物質は、前記リンカーに結合していてもよい。あるいは、標識物質は、前記リンカーに結合していない状態で提供されてもよい。この場合、標識物質は、前記リンカーに結合可能な構造を有する。例えば、標識物質は、リンカーが有する官能基と反応して結合構造を形成することができる官能基を有していてもよい。あるいは、リンカーがビオチンから誘導される基を含む場合には、アビジン又はアビジン誘導体が付加されていてもよい。アビジン誘導体としては、上記と同様のものが挙げられる。標識物質が、リンカーと結合していない状態で提供される場合、ユーザーが、使用前に、リンカーと標識物質との連結反応を行えばよい。
切断試薬は、第1実施形態のキットで挙げたものと同様のものを用いることができる。
第2の態様又は第3の態様にかかるキットは、上記要素に加えて、他の要素を含んでいてもよい。他の要素としては、例えば、標識物質の検出試薬、試料調製試薬、希釈液、バッファー類(ブロッキングバッファー、洗浄バッファー等)、使用説明書等が挙げられる。
本発明の第4の態様は、第1の生体分子構造に対して特異的結合性を有する特異的結合物質と、第1の標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、第1の生体分子構造検出用プローブを用いて、細胞を含む試料中の第1の生体分子構造を検出する工程(A)と、前記第1の生体分子構造検出用プローブ中の前記ジスルフィド結合を切断して、前記第1の標識物質を遊離させる工程(B)と、を含む、生体分子構造の検出方法である。
工程(A)では、第1の生体分子構造に対して特異的結合性を有する特異的結合物質(特異的結合物質20a)と、第1の標識物質(標識物質30a)とが、ジスルフィド結合を含むリンカー(リンカー40a)を介して連結している、第1の生体分子構造検出用プローブ(生体分子構造検出用プローブP1)を用いて、細胞を含む試料(試料1)中の第1の生体分子構造(生体分子10aが含む生体分子構造)を検出する(図1(A)参照)。
工程(B)では、第1の生体分子構造検出用プローブ(生体分子構造検出用プローブP1)中の前記ジスルフィド結合を切断して、前記第1の標識物質(標識物質30a)を遊離させる(図1(B)参照)。
本実施形態の方法は、上記工程(A)及び(B)に加えて、他の工程を含んでいてもよい。他の工程としては、例えば、第2の生体分子構造に対して特異的結合性を有する特異的結合物質と、第2の標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、第2の生体分子構造検出用プローブを用いて、前記試料中の前記第2の生体分子構造を検出する工程(C)(図1(C)参照);及び生体分子構造検出用プローブP2中のジスルフィド結合を切断して、第2の標識物質を遊離させる工程(D)(図1(D)参照)等が挙げられる。
本実施形態の方法は、前記工程(B)後に、前記工程(C)をさらに含むことができる。図1中、生体分子構造検出用プローブP2が、第2の生体分子構造検出プローブである。工程(C)では、工程(B)後の試料1を生体分子構造検出用プローブP2で処理する。これにより、生体分子構造検出用プローブP2は、特異的結合物質20bを介して、生体分子10bに結合する。
本実施形態の方法は、前記工程(C)後に、前記工程(D)をさらに含むことができる。工程(D)を行うことにより、試料1における標識物質30bのシグナルが消滅させることができる。工程(D)は、上記工程(B)と同様に行うことができる。
本実施形態の方法は、さらに、生体分子構造検出用プローブ中の特異的結合物質の種類を変更して、工程(C)及び工程(D)を繰り返し行う工程(E)を含んでいてもよい。特異的結合物質は、工程(C)及び工程(D)のサイクル毎に、異なるものを用いることが好ましい。生体分子構造検出用プローブ中の標識物質は、サイクル毎に、変更してもよく、変更しなくてもよい。工程(C)及び工程(D)の繰り返し回数は、特に限定されず、任意の回数とすることができる。工程(C)及び工程(D)の繰り返し回数は、例えば、1回以上、2回以上、3回以上、5回以上、10回以上、20回以上、30回以上、40回以上、又は50回以上であってもよい。工程(C)及び工程(D)の繰り返し回数の上限値は特に限定されないが、例えば、500回以下、400回以下、300回以下、200回以下、又は100回以下であってもよい。工程(C)及び工程(D)の繰り返し回数は、例えば、1~100回、1~90回、1~80回、1~70回、1~60回、1~50回、1~40回、1~30回、1~20回、1~10回、又は1~5回等とすることができる。
本実施形態の方法は、一次プローブを用いて行うこともできる。この場合、生体分子構造検出用プローブが結合する生体分子構造は、一次プローブが含む生体分子構造であってもよい。例えば、第1の生体分子構造検出用プローブが結合する第1の生体分子構造は、第1の一次プローブが含む生体分子構造であってもよい。この場合、第1の一次プローブは、試料中の細胞が含む第3の生体分子構造に特異的に結合していてもよい。第2の生体分子構造検出用プローブが結合する第2の生体分子構造は、第2の一次プローブが含む生体分子構造であってもよい。この場合、第2の一次プローブは、試料中の細胞が含む第4の生体分子構造に特異的に結合していてもよい。
本変形例の方法は、工程(A’)を含む。工程(A’)は、第3の生体分子構造(生体分子10aが含む生体分子構造)に対して特異的結合性を有する第1の一次プローブ(特異的結合物質20a)を用いて、細胞を含む試料(試料1)を処理し、前記試料中の第3の生体分子構造に前記第1の一次プローブを結合させること;前記第1の一次プローブが含む第1の生体分子構造に特異的結合性を有する特異的結合物質(特異的結合物質21a)と、第1の標識物質(標識物質30a)とが、ジスルフィド結合を含むリンカー(リンカー40a)を介して連結している、第1の生体分子構造検出用プローブ(生体分子構造検出用プローブP3)を、前記第1の一次プローブに結合させること;及び前記第1の標識物質のシグナルを検出することにより、前記第1の生体分子構造を検出することを含む。
工程(B’)では、第1の生体分子構造検出用プローブ(生体分子構造検出用プローブP3)中の前記ジスルフィド結合を切断して、前記第1の標識物質(標識物質30a)を遊離させる。工程(B’)は、上記工程(B)と同様に行うことができる。
≪工程(C’):図2(C’)参照≫
本変形例の方法は、上記工程(A’)及び(B’)に加えて、工程(C’)を含んでいてもよい。工程(C’)は、第4の生体分子構造(生体分子10bが含む生体分子構造)に対して特異的結合性を有する第2の一次プローブ(特異的結合物質20b)を用いて、細胞を含む試料(試料1)を処理し、前記試料中の第2の生体分子構造に前記第2の一次プローブを結合させること;及び前記第2の一次プローブが含む第2の生体分子構造に特異的結合性を有する特異的結合物質(特異的結合物質21b)と、第2の標識物質(標識物質30b)とが、ジスルフィド結合を含むリンカー(リンカー40b)を介して連結している、第2の生体分子構造検出用プローブ(生体分子構造検出用プローブP4)を、前記第2の一次プローブに結合させること;及び前記第2の標識物質のシグナルを検出することにより、前記第2の生体分子構造を検出することを含む。
本変形例の方法は、上記工程(C’)の後、工程(D’)を含んでいてもよい。工程(D’)では、第2の生体分子構造検出用プローブ(生体分子構造検出用プローブP4)中の前記ジスルフィド結合を切断して、前記第1の標識物質(標識物質30b)を遊離させる。工程(D’)は、上記工程(D)と同様に行うことができる。
本実施形態の方法は、さらに、一次プローブの種類及び生体分子構造検出用プローブ中の特異的結合物質の種類を変更して、工程(C’)及び工程(D’)を繰り返し行う工程(E’)を含んでいてもよい。一次プローブ及び生体分子構造検出用プローブ中の特異的結合物質は、工程(C’)及び工程(D’)のサイクル毎に、異なるものを用いることが好ましい。生体分子構造検出用プローブ中の標識物質は、サイクル毎に、変更してもよく、変更しなくてもよい。工程(C’)及び工程(D’)の繰り返し回数は、特に限定されず、任意の回数とすることができる。工程(C’)及び工程(D’)の繰り返し回数は、例えば、1回以上、2回以上、3回以上、5回以上、10回以上、20回以上、30回以上、40回以上、又は50回以上であってもよい。工程(C’)及び工程(D’)の繰り返し回数の上限値は特に限定されないが、例えば、500回以下、400回以下、300回以下、200回以下、又は100回以下であってもよい。工程(C’)及び工程(D’)の繰り返し回数は、例えば、1~100回、1~90回、1~80回、1~70回、1~60回、1~50回、1~40回、1~30回、1~20回、1~10回、又は1~5回等とすることができる。
<第1の生体分子構造検出用プローブの作製>
(リンカーの作製)
リンカーとして、下記構造のリンカー(1)を用いた。
第1の特異的結合物質として、ラット抗マウスIgG抗体(Rat anti-mouse IgG, Jackson Immuno Research)を用いた。リンカーと第1の特異的結合物質との結合は、リンカーに添付の説明書に従って行った。
標識物質として、FITC標識アビジン(Avidin-FITC、Funakoshi)、又はAlexa 555標識アビジン(Streptavidin, Alexa Fluor 555 conjugate、Thermo Fisher)を用いた。リンカーと標識物質とは、0.1Mの炭酸水素ナトリウム水溶液(pH 8.3)中、室温で30分間反応させることで結合させた。
特異的結合物質として、ヤギ抗ラビットIgG抗体(Goat anti-rabbit IgG, Jackson Immuno Research)を用いたこと以外は、上記第1の生体分子構造検出用プローブの作製方法と同様の方法で第2の生体分子構造検出用プローブを作製した。
実施例1の免疫染色方法の概略を図3に模式的に示す。一次抗体(第1の一次プローブ)としてマウス抗βアクチン抗体(Anti-βActin、Abcam)を試料に反応させた後、2次抗体として前記第1の生体分子構造検出用プローブを反応させた。その後、50mMのTCEP-HClで30分処理した。次いで一次抗体(第2の一次プローブ)としてウサギ抗H2AZ抗体(Anti-H2AZ、Abcam)を試料と反応させた後、2次抗体として前記第2の生体分子構造検出用プローブを反応させた。具体的には、以下のように行った。
結果を図4に示す。図4に示すように、マウス抗βアクチン抗体を一次抗体として反応させた後、前記第1の生体分子構造検出用プローブを反応させることにより、FITCの蛍光に基づきβアクチンを検出することができた(1段目画像)。次いで、50mMのTCEPで30分間処理することにより、FITCが遊離し、FITCの蛍光が消滅した(2段目、右端画像)。
生体分子構造検出用プローブとして、実施例1で作製した第2の生体分子構造検出用プローブを用いた。一次抗体としてウサギ抗H2AZ抗体を用いて、上記と同様に試料と反応させた後、2次抗体として生体分子構造検出用プローブを反応させた(Staining)。その後、0mM、1mM、5mM、20mM、又は50mMのTCEP-HClで処理した(TCEP)。さらに、TCEP処理後の試料に対して、Alexa555標識ヤギ抗ウサギ抗体(Goat anti-Rabbit IgG、Thermo Fisher)又はアビジン標識FITCを反応させた(Re-staining)。
実施例3及び比較例1の免疫染色方法の概略を図6に模式的に示す。実施例3及び比較例1では、1次抗体としてAlexa555標識マウス抗ヒストンH3.1抗体を用い、2次抗体としてAl2xa488標識ヤギ抗マウス抗体を用いた。1次抗体として用いたAlexa555標識抗体は、抗体とAlexa555とのリンカー部位に、ジスルフィド結合又は2-ニトロベンジル基を含んでいる。
特異的結合物質としてマウス抗ヒストンH3.1抗体(Anti-H3.1 antibody、九州大学生体防御医学研究所大川研究室で作成)を用い、標識物質としてアビジン標識Alexa555(Streptavidin, Alexa Fluor 555 conjugate、Thermo Fisher)を用いたこと以外は、上記第1の生体分子構造検出用プローブの作製と同様の方法で、生体分子構造検出用プローブを作製した。
マウス抗ヒストンH3.1抗体(Anti-H3.1 antibody、九州大学生体防御医学研究所大川研究室で作成)に、光開裂リンカーを介してAlexa555が結合された抗体を1次抗体として用いた。光開裂リンカーとしては、光開裂基として2-ニトロベンジル基を含むものを用いた(PC-Biotin-PEG4-NHS carbonate、フナコシ)。
一次抗体として、ウサギ抗H2AZ抗体(Anti-H2AZ、Abcam)を用い、2次抗体としてAlexa 488標識ヤギ抗ウサギ抗体を用いて、上記と同様に免疫染色を行った(Staining)。その後、0mM、5mM、20mM、又は50mMのTCEP-HClで30分間処理した(TCEP)。次いで、Alexa 488標識ヤギ抗ウサギ抗体により再度染色を行った(Restaining)。
<生体分子構造検出用プローブの作製>
特異的結合物質として、図10に示す各タンパク質に特異的な抗体を用いたこと以外は、実施例1と同様の方法で、各生体分子構造検出用プローブを作製した。
細胞培養皿で培養した細胞に4%のパラホルムアルデヒド(パラホルムアルデヒド、ナカライテスク)を加えて15分間反応させることで細胞の固定を行った。固定化した細胞に0.5% TritonX-100を添加し、5分間反応させることで透過処理を行った。その後、ブロッキング溶液(Blocking One-P、ナカライテスク)を加えて10分間反応させることでブロッキングを行った。次に、リンカー標識をした抗aTublinマウスIgG抗体(10%ブロッキング溶液で500倍に希釈)を室温で30分間、細胞に反応させた。反応後、細胞をPBSで5分x3回洗浄し、蛍光観察を行った。蛍光観察後、細胞に50mMのTCEPを添加し室温30分間処理を行った。
結果を図10に示す。各タンパク質に対する抗体を特異的結合物質として含む生体分子構造検出用プローブを用いることにより、免疫染色により各タンパク質を検出することができた。TCEP処理により、その前に行った免疫染色の標識物質が除去され、その後の免疫染色に影響しないことが確認された。
<生体分子構造検出用プローブの作製>
特異的結合物質として、図11に示す各タンパク質に特異的な抗体を用いたこと以外は、実施例1と同様の方法で、各生体分子構造検出用プローブを作製した。
図11に示す各タンパク質に特異的な抗体を用いたこと以外は、実施例10と同様の方法で、連続免疫染色を行った。
連続免疫染色で得られた各タンパク質に対する免疫染色画像から、MATLAB(登録商標)(MathWorks,Inc.)を用いて、単一細胞レベルで各タンパク質シグナルを定量化した。図11に、その結果をプロテオームデータとして示した。連続免疫染色により、単一細胞レベルで、プロテオーム解析が可能なことが示された。
図11に示すデータを次元圧縮(UMAP)して、類似した細胞の種類毎に、5つのグループにグループ化した。図12に、その結果を示した。連続免疫染色により、プロテオーム解析による細胞のグループ化が可能なことが示された。
免疫染色画像に存在する細胞の位置を点として示し、上記でグループ化した5つのグループの細胞の位置を、各グループに対応する色の点として示した。その結果を図13に示す。
10a,10b 生体分子
20a,20b,21a,21b 特異的結合物質
30a,30b 標識物質
40a,40b リンカー
P1,P2,P3,P4 生体分子構造検出用プローブ
Claims (12)
- 生体分子構造に対して特異的結合性を有する特異的結合物質と、標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、生体分子構造検出用プローブ。
- 前記特異的結合物質が抗体である、請求項1に記載の生体分子構造検出用プローブ。
- 前記標識物質が蛍光色素である、請求項1又は2に記載の生体分子構造検出用プローブ。
- 請求項1~3のいずれか一項に記載の生体分子構造検出用プローブと、
ジスルフィド結合の切断試薬と、
を含む、生体分子構造検出用キット。 - 生体分子構造に対して特異的結合性を有する特異的結合物質と標識物質とを連結するためのリンカーであって、ジスルフィド結合を含むリンカーと、
前記リンカーに結合している若しくは結合可能な標識物質と、
ジスルフィド結合の切断試薬と、
を含む、生体分子構造検出用キット。 - 前記特異的結合物質が抗体である、請求項5に記載の生体分子構造検出用キット。
- 前記標識物質は蛍光色素である、請求項5又は6に記載の生体分子構造検出用キット。
- 第1の生体分子構造に対して特異的結合性を有する特異的結合物質と、第1の標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、第1の生体分子構造検出用プローブを用いて、細胞を含む試料中の第1の生体分子構造を検出する工程(A)と、
前記第1の生体分子構造検出用プローブ中の前記ジスルフィド結合を切断して、前記第1の標識物質を遊離させる工程(B)と、
を含む、生体分子構造の検出方法。 - 前記工程(B)後、
第2の生体分子構造に対して特異的結合性を有する特異的結合物質と、第2の標識物質とが、ジスルフィド結合を含むリンカーを介して連結している、第2の生体分子構造検出用プローブを用いて、前記試料中の前記第2の生体分子構造を検出する工程(C)、
をさらに含む、請求項8に記載の生体分子構造の検出方法。 - 前記第1の標識物質と前記第2の標識物質とが、同一の標識物質である、請求項9に記載の生体分子構造の検出方法。
- 前記第1の生体分子構造が、前記細胞が含む第3の生体分子構造に特異的に結合する第1の一次プローブが含む生体分子構造である、
請求項8~10のいずれか一項に記載の生体分子構造の検出方法。 - 前記第1の生体分子構造が、前記細胞が含む第3の生体分子構造に特異的に結合する第1の一次プローブが含む生体分子構造であり、
前記第2の生体分子構造が、前記細胞が含む第4の生体分子構造に特異的に結合する第2の一次プローブが含む生体分子構造である、
請求項9又は10に記載の生体分子構造の検出方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022566947A JPWO2022118862A1 (ja) | 2020-12-01 | 2021-11-30 | |
EP21900614.5A EP4239335A1 (en) | 2020-12-01 | 2021-11-30 | Biomolecule structure detection probe, biomolecule structure detection kit, and method for detecting biomolecule structure |
US18/038,653 US20240044906A1 (en) | 2020-12-01 | 2021-11-30 | Biomolecule structure detection probe, biomolecule structure detection kit, and method for detecting biomolecule structure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020199800 | 2020-12-01 | ||
JP2020-199800 | 2020-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022118862A1 true WO2022118862A1 (ja) | 2022-06-09 |
Family
ID=81853225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/043986 WO2022118862A1 (ja) | 2020-12-01 | 2021-11-30 | 生体分子構造検出用プローブ、生体分子構造検出用キット、及び生体分子構造の検出方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240044906A1 (ja) |
EP (1) | EP4239335A1 (ja) |
JP (1) | JPWO2022118862A1 (ja) |
WO (1) | WO2022118862A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6324155A (ja) * | 1986-04-03 | 1988-02-01 | スカルボ インコ−ポレイテツド,ウエスト コ−スト | 結合測定法に使用される開裂可能な標識 |
US20040259164A1 (en) * | 2003-06-06 | 2004-12-23 | President And Fellows Of Harvard College | Capture and release based isotope tagged peptides and methods for using the same |
JP2005511058A (ja) * | 2001-12-04 | 2005-04-28 | ソレックサ リミテッド | 標識ヌクレオチド |
JP2007312776A (ja) * | 2004-06-24 | 2007-12-06 | Scripps Res Inst:The | 切断可能なリンカーを有するアレイ |
JP2016525344A (ja) * | 2013-06-12 | 2016-08-25 | ザ ジェネラル ホスピタル コーポレイション | 標的分子のマルチプレックス検出のための方法、キット、およびシステム、ならびにそれらの使用 |
JP2020199800A (ja) | 2019-06-06 | 2020-12-17 | 株式会社Jvcケンウッド | ドライブレコーダ |
-
2021
- 2021-11-30 JP JP2022566947A patent/JPWO2022118862A1/ja active Pending
- 2021-11-30 US US18/038,653 patent/US20240044906A1/en active Pending
- 2021-11-30 EP EP21900614.5A patent/EP4239335A1/en active Pending
- 2021-11-30 WO PCT/JP2021/043986 patent/WO2022118862A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6324155A (ja) * | 1986-04-03 | 1988-02-01 | スカルボ インコ−ポレイテツド,ウエスト コ−スト | 結合測定法に使用される開裂可能な標識 |
JP2005511058A (ja) * | 2001-12-04 | 2005-04-28 | ソレックサ リミテッド | 標識ヌクレオチド |
US20040259164A1 (en) * | 2003-06-06 | 2004-12-23 | President And Fellows Of Harvard College | Capture and release based isotope tagged peptides and methods for using the same |
JP2007312776A (ja) * | 2004-06-24 | 2007-12-06 | Scripps Res Inst:The | 切断可能なリンカーを有するアレイ |
JP2016525344A (ja) * | 2013-06-12 | 2016-08-25 | ザ ジェネラル ホスピタル コーポレイション | 標的分子のマルチプレックス検出のための方法、キット、およびシステム、ならびにそれらの使用 |
JP2020199800A (ja) | 2019-06-06 | 2020-12-17 | 株式会社Jvcケンウッド | ドライブレコーダ |
Non-Patent Citations (1)
Title |
---|
CAULUM MEGHAN M., MURPHY BRIAN M., RAMSAY LAUREN M., HENRY CHARLES S.: "Detection of Cardiac Biomarkers Using Micellar Electrokinetic Chromatography and a Cleavable Tag Immunoassay", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 79, no. 14, 1 July 2007 (2007-07-01), US , pages 5249 - 5256, XP055936698, ISSN: 0003-2700, DOI: 10.1021/ac070452v * |
Also Published As
Publication number | Publication date |
---|---|
EP4239335A1 (en) | 2023-09-06 |
JPWO2022118862A1 (ja) | 2022-06-09 |
US20240044906A1 (en) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240085424A1 (en) | Antigen-coupled immunoreagents | |
JP7097885B2 (ja) | 水溶性ポリマー色素 | |
CN105980855B (zh) | 利用可编程核酸探针的高通量且高度多路复用的成像 | |
US20210181191A1 (en) | Antigen detection using photocleavable labels | |
US11808770B2 (en) | Proximity assays using chemical ligation and hapten transfer | |
US20190112356A1 (en) | High-affinity immunopolymers | |
JP6302560B2 (ja) | ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法 | |
US20230174585A1 (en) | Peptide nucleic acid conjugates | |
Wolf et al. | Strategies for Site‐Specific Labeling of Receptor Proteins on the Surfaces of Living Cells by Using Genetically Encoded Peptide Tags | |
WO2022118862A1 (ja) | 生体分子構造検出用プローブ、生体分子構造検出用キット、及び生体分子構造の検出方法 | |
JP2022046522A (ja) | ペプチド核酸コンジュゲート | |
US11614445B2 (en) | Background blockers for binding assays | |
US20140134645A1 (en) | Method of isolating or counting target cells by using photocleavable linker coupled with fluorescent dye | |
US20220155311A1 (en) | Multiplexed Imaging with Nanobody Probes | |
JP2022517957A (ja) | フレキシブル検出システム | |
JP2017049184A (ja) | 抗体のヌクレオチド結合部位(nbs)を利用して蛍光標識された抗体 | |
Kageler et al. | Tools to investigate the cell surface: Proximity as a central concept in glycoRNA biology | |
CN117264076A (zh) | 标记多肽、修饰多肽、这些多肽的制造方法、含这些多肽的试剂及目标物质的测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21900614 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18038653 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022566947 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021900614 Country of ref document: EP Effective date: 20230530 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |